Exploration of the Molecular Mechanisms Behind the Effects of Physical Exercise on Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 55
- Locations
- 1
- Primary Endpoint
- Miller-Payne grade
Study Overview
Brief Summary
The goal of this clinical trial is to learn how regular physical exercise affects breast cancer patients' response to standard neoadjuvant chemotherapy (NAC) and to gain an insight into the molecular mechanisms underlying the effects of exercise on cancer biology. of exercise-induced alterations in cancer gene expression and the immune tumor microenvironment. The main questions it aims to answer are:
- Does a high-intensity interval training (HIIT) program during treatment improve patients' response to NAC and quality of life as compared to low level of physical activity during the treatment?
- What are the differences in the residual tumor gene expression and tumor infiltrating immune cell profile between patients taking HIIT during the NAC and patients with low level of physical activity?
- What are the roles of extracellular vesicles (EVs) in mediating the effects of exercise on cancer progression?
Patients in HIIT group will undergo a personalized HIIT program consisting of 3 training sessions per week for the whole duration of NAC, whereas patients from the control group (Ctrl) will be advised to maintain their usual level of physical activity during NAC. After the breast surgery, response to NAC will be assessed by Miller-Payne grading. Tumor and normal breast tissue specimens will be collected for RNA sequencing analysis. Blood samples will be collected before and immediately after the training for the analysis of RNA and protein cargo of circulating EVs.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 30 Years to 65 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Primary breast cancer; stage IIA-B, IIIA-C (TNM: T1-4, N0-3, M0) at diagnosis
- •Diagnosis established by core needle biopsy
- •Age 30-65 years
- •Prescribed doxorubicin/cyclophosphamide-based NAC
- •Oral and written consent
Exclusion Criteria
- •Cardiac pathologies
- •Pregnancy
- •Blood transfusion in the last six months
- •Another oncological disease
- •Previous chemotherapy, hormonal or X-ray treatment
- •Participation in another clinical trial
- •Currently performing more than 180 min of moderate to high intensity aerobic training per week
Arms & Interventions
High-intensity interval training (HIIT)
High-intensity interval training during neoadjuvant chemotherapy
Intervention: High-intensiy interval training (Behavioral)
Low level of physical activity (CON)
Advised to maintain usual level of physical activity during neoadjuvant chemotherapy
Outcomes
Primary Outcomes
Miller-Payne grade
Time Frame: 6 months
Response to NAC assessed by histological examination of residual tumor at surgery using Miller-Payne grading from 1 to 5, where grade 1 means no response or some alterations to individual malignant cells but no reduction in overall cellularity, whereas grade 5 is a pathological complete response.
Gene expression profile
Time Frame: 12 months
Alterations in the tumor gene expression profile will be assessed by RNA sequencing of surgical tumor and normal breast tissue specimens
Secondary Outcomes
- Protein cargo of extracellular vesicles(Before intervention and after 6 months)
- Breast cancer-related quality of life(6 months)
- 30 sec sit-to-stand test(Before intervention and after 6 months)
- 6-minute walk test(Before intervention and after 6 months)
- Number and phenotype of tumor-infiltrating immune cells(12 months)
- Global health-related quality of life(6 months)
- VO2 peak(Before intervention and after 6 months)
- RNA cargo of extracellular vesicles(Before intervention and after 6 months)